prognosis in chronic liver disease (3) , assessment of the rate of fibrogenesis could be useful in predicting outcome in conditions such as EHBA.
During hepatic fibrogenesis metabolism of ECM components, such as collagens (in particular collagens type I and 111), glycoproteins, proteoglycans, and glycosaminoglycans, is increased within the liver (3) . Measurement of serum concentrations of by-products of ECM metabolism has therefore been proposed as markers of hepatic fibrogenesis (4) and could be of value in assessing prognosis in chronic liver disease. For example, serum concentrations of the glycosaminoglycan HA and PIIINP have been shown to be of prognostic value in adults with primary biliary cirrhosis (5, 6) . Serum HA may also, as we have shown in preliminary studies (7) , be useful in infants with cholestatic liver disease, but PIIINP is of no apparent value in infancy (8) , maybe because the high levels normally found during growth mask any increase due to liver fibrogenesis (9) . Because the PIIINP assay used in these early studies (10) measured several different antigens in serum (ll), it is not clear whether a more specific assay would allow easier detection of PIIINP changes in pediatric liver disease. In recent years, we have developed such a PIIINP assay (12) and also assays for PICP and PINP (13, 14) . These latter assays may be useful in assessing hepatic fibrogenesis, but have not yet been applied to either adult or pediatric liver disease.
The aim of this study was therefore to measure serum HA, PIIINP, PICP, and PINP in patients with EHBA, both before and serially after portoenterostomy, and to determine their value in the assessment of prognosis and disease activity in EHBA.
METHODS

Patients.
Twenty four patients with EHBA (13 boys, 11 girls, assessed from <4 mo of age) were studied longitudinally, patients being selected as those in whom serial serum samples had been stored at -20°C both before and after portoenterostomy. Patients were grouped for this study according to their outcome, group A consisted of 10 patients who died (age at death = 7-20 mo of age, median 9), group B of six who required LT (age at LT = 1.1-4.8 y, median 2.6), and group C of eight who were jaundice-free and well at 5 y of age ( Table   . \ 
1).
EHBA was diagnosed from clinical, biochemical, radiologic, and histologic findings and confirmed at laparotomy. At this stage, each group of patients had similarly raised serum bilirubin, AST, and GGT regardless of prognosis (Table 1) . Portoenterostomy was performed in all patients between 2.5 and 16 wk of age, with significantly later surgery in group A compared with groups B and C ( In contrast in group C, serum bilirubin fell to normal in all patients after portoenterostorny and all remained clinically well during the first 5 y of life, apart from one episode of suspected cholangitis.
Serum samples used for this study were obtained from each patient before portoenterostorny, at 6 mo of age and then at 6 monthly intervals until death, LT or 5 y of age. Each sample was obtained primarily for management purposes and excess serum remaining after routine biochemical analysis was stored at -20°C for between 1 and 4 y. We have previously found such storage conditions to have no effect on serum concentrations of HA, PIIINP or PICP; stability of PINP could only be established over a 2-y period because the PINP assay has only been developed in the last 2 y (14) . A total of 133 samples were available and consisted of 2-4 samples per patient (median 3) from subjects in group A, 2-8 per patient (median 6) in group B and 4-9 per patient (median 9) in group C.
Serum analyses. Serum concentrations of HA were measured using 100 E*.L undiluted serum in a commercial radiometric assay (~harmacia Diagnostics, Uppsala, Sweden) (15) in which HA in the sample bound to 125~-labeled specific HABP isolated from bovine cartilage (lZ51-I-I~J3p). Free lZ51-HABP was then bound to exogenously added HA covalently linked to Sepharose and the complex separated by centrifugation. The amount of bound radioactivity, which was inversely proportional to the amount of HA in the original serum sample, was then measured. Serum samples containing more than 350 pg HA/L fell outside the range of the standard curve and were therefore diluted with the zero HA standard solution and reassayed. The interassay coefficient of variation for the HA assay was <lo% (10 assays; serum HA concentrations 65 pg/L and 453 pg/L).
Serum concentrations of PIIINP (12) and PICP (13) were measured using 100 p L of diluted serum in commercial RIA (Orion Diagnostica, Espoo, Finland), using a 1 in 6 dilution in PBS for serum samples obtained from patients less than 6 mo of age, 1 in 3 for samples at 6-12 mo of age and 1 in 2 for samples at 1-5 y of age. For each assay, 100 p L of the appropriate dilution were incubated with rabbit antibodies against either human PIIINP or PICP and 1 2 5~-~~~~ or 1 2 5~-~~~~ for 2 h at 37°C. Bound 1 2 5~-~~~~~~ or 1 2 5~-~~~~ was then separated and measured, and the concentration of PIIINP or PICP in the original sample read from the appropriate standard curve. Interassay coefficients of variation were <8% for both assays (10 assays; PIIINP at 2.1 and 12.5 pg/L, PICP at 121 and 400 pg/L).
Serum PINP was measured using a newly developed inhouse RIA, which uses rabbit antibodies against human PINP (14), 1 2 5~-P~~~ and 100 p L of diluted serum, using dilutions of 1 in 100 for samples obtained from patients less than 3 mo of age, 1 in 25 for samples at 3-6 mo of age and 1 in 10 for samples at 6 mo-5 y of age. The interassay coefficient of variation was <8% (10 assays; serum PINP at 82 and 462 pg/L).
Because of the age variation in serum HA, PIIINP, PICP, and PINP in healthy infants and children (7, (16) (17) (18) , absolute values were corrected for age by conversion to SDS (Table 1) using control values previously obtained in this laboratory (7, (16) (17) (18) . For this:
ance, followed by t tests. After portoenterostomy, the change between surgery and 6 mo of age for each of the three groups was assessed using the paired t test. After 6 mo of age, longitudinal data for each patient was summarized as peak values (19) and differences between group summary values assessed using analysis of variance and t tests. All statistical differences were expressed as p values and 95% CI of the difference (20) . The value of serum markers as early predictors of outcome were assessed using standard methods (21) .
SDS
RESULTS
-observed value -mean for age and sex = matched controls -standard deviation for age and sex-matched controls Serum concentrations of HA. Serum HA-SDS showed a different pattern both before and after portoenterostomy in patients with different outcomes. In those with a poor prognosis (group A and B), HA-SDS was significantly increased compared with normal before portoenterostomy ( Table 1 ) and then increased even further in every child ( p < 0.001, 95% CI = 24.1-83.5 for group A and 4.1-36.8 for group B) by 6 mo of age ( Fig. 1) . HA-SDS then remained high in these groups ( Fig. with the normal range (i.e. mean -t 2 X SD) was defined as SDS -2.0 to SDS f2.0.
Data analysis. Serologic data were found to be normally distributed within each group and parametric methods were therefore used for statistical analysis, using appropriate methods at each stage of follow-up. Before portoenterostomy, differences between groups were assessed using analysis of vari- 1) until either death (group A) or LT (group B), with generally higher values in group A. In contrast, those patients with a better prognosis (group C) showed relatively small increases in HA-SDS before portoenterostomy (Table I) , no significant change between surgery and 6 mo of age (Fig. I) , and then remained within the normal range for age during further follow-up, except for one isolated occasion in one patient (Fig. 1) . At every stage of follow-up, values of HA-SDS were greater in groups A and B compared with group C at every stage of follow-up (Fig. I) , with significantly greater values before portoenterostomy (Table 1 ; A versus C-p < 0.005, 95% CI 2.8-11.8; B versus C-p < 0.01,95% CI 2.3-10.9), at 6 mo of age (A versus C-p < 0.001, 95% CI 30.6-91.8; B versus C-p < 0.001, 95% CI 15.6-39.8) and during further follow-up (A versus C-p < 0.001, 95% CI 28.5-90.4; B versus C-p < 0.01, 95% CI = 13.0-35.4).
Serum concentrations of PZZZNP. Serum PIIINP SDS was similar in all three groups before portoenterostomy, regardless of outcome (Table 1) . However, after surgery, those with a poor prognosis showed a different trend compared with those with a better prognosis. There was a significant increase in PIIINP SDS in group A after surgery (p < 0.01, 95% CI = 2.2-6.1) and in group B a trend toward an increase (Fig. 2) . PIIINP SDS then remained high in both groups until 12-18 mo GROUP A GROUP B r of age (Fig. 2) , after which PIIINP fell to normal even though there was continuing clinical deterioration (Fig. 2) . In contrast, group C showed a fall in PIIINP SDS to normal after surgery and then remained persistently normal (Fig. 2) , except on two isolated occasions (Fig. 2) , one of which coincided with raised HA and suspected cholangitis.
Serum concentrations of PICP. Serum PICP showed a mixed response in the three groups before portoenterostomy, with significantly decreased values in group A, normal values in group B and raised values in group C (Table 1) . After portoenterostomy however all three groups showed broadly the same trend irrespective of outcome, with normal PICP SDS throughout (Fig. 2) .
Serum concentrations of PZNP. Serum PINP SDS showed a similar trend in all three groups both before and after portoenterostomy, regardless of prognosis. PINP SDS was significantly decreased below the lower limit of normal for age in each group before surgery (Table I) , increased to values within the normal range by 6 mo of age (p < 0.001; 95% CI = 1.1-4.2 for group A, 1.0-4.5 for group B, and 0.2-4.3 for group C). PINP SDS values then remained within the normal range during the rest of follow-up (Fig. 2) .
Serum bilirubin, AST, and GGT. Serum bilirubin was similarly increased in all three groups before portoenterostomy (Table I ), but then showed a different trend after surgery depending on outcome (Fig. 1) . Bilirubin fell in 4 of the 10 patients in group A and 5 of the 6 in group B (Fig. I) , but, except for one patient, did not become normal and remained raised throughout follow up (Fig. 1) ; in contrast, bilirubin fell to normal in all 8 patients in group C by 6 mo of age and remained normal throughout, except in one patient where an isolated increase in bilirubin was observed during an episode of suspected cholangitis.
Serum AST was similar in all three groups of patients regardless of prognosis both before portoenterostomy (Table  I) , at 6 mo of age and during further follow-up (Fig. 1) .
Serum GGT was similarly increased in all three groups before portoenterostomy regardless of prognosis (Table 1 ) but then remained unchanged by 6 mo of age in groups A and B, but rose significantly in group C (p < 0.001, 95% CI = 118-505 IUD,), and remained above normal in all three groups during the rest of follow-up (Fig. 1) .
Relationship between serum analytes andprognosis. When assessed as a marker of prognosis, HA SDS was raised above 2.0 before portoenterostomy in 15 of 16 patients with a poor prognosis (groups A and B), but only in 2 of 8 with a better prognosis (group C); HA SDS >2.0 therefore identified patients who would die (group A) or require LT (group B) with 88% positive predictive value (95% CI = 64-99%) and 86% negative predictive value (42-100%) with 94% sensitivity (70-100%) and 75% specificity (35-97%).
HA SDS at 6 mo of age was also of prognostic value, HA SDS >2.0 identifying patients who would die or require LT with a positive predictive value of 89% (65-99%), negative predictive value of 100% (54-loo%), sensitivity of 100% (79-100%) and specificity of 75% (35-97%); increasing the cut-off value of HA SDS to 4.0 increased all predictive values to 100%. In addition, serum HA SDS at 6 mo of age also gave an idea of the time of survival, with significant correlations between age at death or LT and HA SDS (r, = -0.58, p < 0.03).
Serum bilirubin at 6 mo of age was also of prognostic value, values >30 prnolb identifying patients who would die or require LT with 100% positive predictive value (78-loo%), 89% negative predictive value (52-loo%), 94% sensitivity (70-99%), and 100% specificity (63-100%). However, it was notable that in contrast to HA SDS (which increased between surgery and 6 mo of age in all 16 patients with a poor prognosis; Fig. I ), serum bilirubin fell in 9 of the 16 patients over the same period (Fig. 1) .
Values found for serum PIIINP, PICP, PINP, AST, or GGT were of no prognostic value either before or after surgery.
DISCUSSION
This study shows, for the first time, a serologic marker, HA, which may predict the outcome of EHBA, values of HA greater than 200 pg/L at diagnosis identifying with 88% positive predictive value those patients who will die or require LT before 5 y of age. Although these results obviously need confirmation in a larger group of prospectively studied, unselected patients, they do indicate that early measurement of serum HA may be of potential major importance in assessing the prognosis of EHBA. Such prognostic information would be invaluable when planning management in EHBA, allowing time for patients with a poor prognosis and their families to be prepared for LT before the patient has developed end-stage liver disease and while the chances of successful LT are optimal (1) .
Because no other serologic marker, including bilirubin (22), provides such clear-cut prognostic information in EHBA, we suggest that serum HA, which can be measured by a simple and reproducible assay and therefore lends itself readily to the routine clinical chemistry laboratory, be introduced into the profile of liver function tests currently performed when assessing and diagnosing EHBA. In addition, serum HA may also be a valuable adjunct to standard serologic tests during follow-up of EHBA, because longitudinal changes in HA found in this study were clearly related to clinical status.
In adult liver disease (5, 24), increases in serum HA have been largely attributed to impaired clearance of HA by damaged sinusoidal endothelial cells, which remove over 95% of HA from the circulation (23) . A similar situation may also occur in EHBA. However, the raised serum HA observed in EHBA could also result, in part at least, from an increased output of HA from the liver during fibrogenesis, when the metabolism of many ECM components, including HA, is increased (3).
In addition to serum HA, we also investigated the role of other serum markers of ECM metabolism (4) in EHBA. Serum PIIINP was of no value in assessing prognosis before portoenterostomy, but did appear to be related to disease progression after portoenterostomy for the first 1-2 y of life. Thereafter, PIIINP fell to normal even in the presence of clinical deterioration, raising the possibility that the increases in PIIINP reflect increased output of PIIINP from the liver in the early stages of cirrhosis when type I11 collagen is formed very rapidly (25) ; the subsequent fall in PIIINP may later reflect the decline in type I11 collagen formation as cirrhosis becomes established and formation of type I collagen predominates (25) . However, like HA, impaired clearance could also play a contributory role to raised serum PIIINP in EHBA, because this is cleared by scavenger receptors on hepatic sinusoidal endothelial cells (26) which may be damaged in EHBA. However, we suspect that decreased clearance may not significantly affect serum PIIINP in this study because serum PINP, which is cleared by the same receptor as PIIINP (27) , was not increased with PIIINP in EHBA.
These normal or low concentrations of PINP found in this study (even in very severe disease) therefore at first were surprising because type I collagen metabolism is increased in EHBA as well as type I11 (28) . We suggest that, inasmuch as type I collagen is found in bone as well as soft tissues and bone forms the largest pool of this collagen in the body, serum PINP is likely to be skeletal in origin (29) . The low serum PINP seen in patients in this study could therefore be reflecting some early biochemical manifestation of bone disease, a common complication of cholestatic disease in infancy (30) . Further studies in larger groups of EHBA patients, with and without overt bone disease, are needed to determine whether low serum PINP is related to bone metabolism and could have a clinical role in assessing skeletal abnormality in EHBA.
Another surprising finding in this study was that serum PICP did not show the same trend as PINP, even though both are released into the circulation in equimolar amounts during synthesis of type I collagen. The only obvious explanation for this discrepancy is that the two propeptides are cleared by different receptor mechanisms, PICP being cleared by the mannose receptor on liver sinusoidal endothelial cells (31) and PINP by the scavenger receptor on these same cells (27) , which also clears PIIINP. Although highly speculative, we suggest that, in EHBA, both serum PINP and PICP are low due to a defect in bone metabolism; at the same time, the mannose receptor (which is more labile than the scavenger receptor) may be damaged resulting in impaired clearance of PICP. This means the low PICP due to decreased collagen metabolism in bone is counterbalanced by the increased PICP due to decreased clearance, resulting in normal serum PICP concentrations.
The findings of this study therefore allow us to conclude that serum HA may be a potentially important test in assessing, at an early stage, the prognosis in infants with EHBA. In addition, routine measurement of serum HA may also be a useful complementary test in monitoring EHBA, increases in HA, even in the presence of falling bilirubin, indicating disease progression. In contrast, serum PIIINP served as a marker of disease progression only in the first 18 mo of life and was of no prognostic value, whereas serum PICP was of no value at all in EHBA. Serum PINP was of no value in assessing liver disease but may prove to be useful in the biochemical assessment of skeletal abnormalities in EHBA; further studies are, however, required in larger numbers of patients to confirm this.
